Research yields evidence-based findings, and healthcare providers apply these findings as “best practices” to care for patients safely and effectively. At the Care Coordination Institute (CCI), we believe that research distilled into evidence-based best practices can lead to improvements in quality, healthcare costs and the patient experience.
CCI focuses on research questions that are important to those working in the clinical setting and provides research inquiries that will generate actionable results. The research results can provide insights for the innovative delivery of quality healthcare to patients and can be broadly applied across practice settings and patient populations. CCI research also serves to support physician practices and community partners in the application of evidence-based best practices.
Current Research Projects
TIP TOP (Tobacco Intervention in Primary Care, Treatment Options for Providers) is an active smoking cessation comparative effectiveness trial run by Dr. Matthew Carpenter and his team at the Medical University of South Carolina. Below are the links to training associated with the trial. Note: The following training links must be opened using Firefox or Chrome, not Internet Explorer.
Chapter 1: Introduction & thank you
Chapter 2: Background smoking cessation and the 5 As
Chapter 3: Medication Information
Chapter 4: Study Background and Overview
Chapter 5: Procedure Overview
Chapter 6: Screening
Chapter 7: Consenting
Many CCI research initiatives include partnerships with academic, agency and clinical partners, as well as payers and healthcare decision makers. Collaborative initiatives provide multi-faceted research approaches and facilitate opportunities to translate meaningful research findings into sustainable health policy change at the practice, state and national levels. CCI is in a continuous learning environment by which research informs best practice and health policy insights for the purposes of delivering the highest quality of care to our patients.
CCI staff authored or contributed to the following publications.
Original, peer-reviewed publications:
- Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment resistant hypertension in a community-based practice network. Hypertension. 2013; 62:691–697.
- Egan BM, Laken MA. Pre-hypertension: Rationale for pharmacotherapy. Curr Hypertens Rep. 2013;6:669–675.
Egan BM, Li J, Shatat IF, Fuller JM, Sinopoli A. Closing the gap in hypertension control between younger and older adults: NHANES 1988 to 2010. Circulation. 2014;129:2052–2061.
- Egan BM, Li Jiexiang, Wolfman TE, Sinopoli A. Demographic differences in concurrent vascular risk factor control in patients with diabetes: NHANES 1988–2010. J Am Soc Hypertens. 2014;8:394–404.
- Ostrye J, Hailpern SM, Jones J, Egan B, Chessman K, Shatat I. The efficacy and safety of intravenous hydralazine for the treatment of hypertension in the hospitalized child. Pediatric Nephrol. 2014:29:1403–1409.
- Hudson SM, Hiott DB, Cole J, Davis R, Egan BM, Laken MA. Increasing capacity for quality improvement in under-resourced primary care settings. Qual Manag Health Care. 2014;23:155–162.
- Egan BM, Li J, Small J, Nietert PJ, Sinopoli A. The growing gap in hypertension control between insured and uninsured adults: NHANES 1988–2010. Hypertension. 2014; (HYPERTENSIONAHA.114.04276 (epub ahead of print).
- Hailpern SM, Egan BM, Lewis KD, Wagner C, Shattat GH, Al Qaoud DI, Shatat IF. Blood pressure, heart rate and CNS stimulant medication use in children with and without ADHD: Analysis of NHANES data. Front Ped Nephrol. 2014;2:(in press [doi: 10.3389/fped.2014.00100]).
- Egan BM, Li J, Hutchison FN, Ferdinand KC. Hypertension in the United States 1999–2012: Progress toward Healthy People 2020 goals. Circulation. 2014;(in press).
- Boan AD, Egan BM, Bachman DL, Adama RJ, Feng W, Jauch EC, Ovbiagele B, Lackland DT. Antihypertensive medication persistence one year post stroke hospitalization. J Clin Hypertens. 2014;(in press).
Book chapters, editorials and reviews:
- Egan BM. Commentary: Prediction of incident hypertension: Health implications of data mining in the ‘Big Data’ era. J Hypertension. 2013;31:2123–2124.
- Egan BM. Editorial commentary. Collectrin, an X-linked, ACE2 homolog, causes hypertension in a rat string through gene-gene and gene-environment interaction: Relevance to human hypertension. Circulation. 2013;128:1727-1728.
- Egan BM. Editorial Commentary: Plasma lipidomic profile signature of hypertension in Mexican-American families. Hypertension. 2013;62:453–454.
- Egan BM. Aldosterone antagonists in treatment resistant hypertension. Semin Nephrol. 2014;34:340–348.
- Egan BM. Treatment of hypertension in blacks. In: Up to Date, Ed., John P. Forman, section eds., George L. Bakris, Normal M. Kaplan, updated 01/01/2014.
- Egan BM. Treatment of hypertension in the elderly, particularly isolated systolic hypertension. In: Up to Date, Ed., John P. Forman, section eds., George L. Bakris, Normal M. Kaplan, Kenneth E. Schmader, updated 01/02/2014
- Egan BM, “Opportunities for multidisciplinary ASH Clinical Hypertension Specialists in an era of population health and accountable care: ASH leadership message. J Am Soc Hypertens. 2014;8:451–456.
- Lackland DT, Egan BM. High-Risk Hypertension in African Americans. In: Hypertension in African Americans. K. Ferdinand, Ed., 2014;(in press).